APA (7th ed.) Citation

Ramanathan, S., Custodio, J. M., Wei, X., Wang, H., Fordyce, M., Dave, A., . . . Kearney, B. P. (2016). Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects. Journal of acquired immune deficiency syndromes (1999), 72(3), 281. https://doi.org/10.1097/QAI.0000000000000959

Chicago Style (17th ed.) Citation

Ramanathan, Srini, Joseph M. Custodio, Xuelian Wei, Hui Wang, Marshall Fordyce, Ami Dave, Kah Hiing J. Ling, Javier Szwarcberg, and Brian P. Kearney. "Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects." Journal of Acquired Immune Deficiency Syndromes (1999) 72, no. 3 (2016): 281. https://doi.org/10.1097/QAI.0000000000000959.

MLA (9th ed.) Citation

Ramanathan, Srini, et al. "Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects." Journal of Acquired Immune Deficiency Syndromes (1999), vol. 72, no. 3, 2016, p. 281, https://doi.org/10.1097/QAI.0000000000000959.